DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,109 filers reported holding DANAHER CORPORATION in Q4 2016. The put-call ratio across all filers is 0.26 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93,214,417 | -1.4% | 375,713 | -4.6% | 3.32% | +8.2% |
| Q2 2023 | $94,535,541 | -5.8% | 393,898 | -1.1% | 3.06% | -11.8% |
| Q1 2023 | $100,338,406 | -6.1% | 398,105 | -1.1% | 3.48% | -9.6% |
| Q4 2022 | $106,850,872 | +2.1% | 402,573 | -0.6% | 3.84% | -6.3% |
| Q3 2022 | $104,659,000 | +1.4% | 405,200 | -0.5% | 4.10% | +4.9% |
| Q2 2022 | $103,217,000 | -15.8% | 407,137 | -2.6% | 3.91% | +1.4% |
| Q1 2022 | $122,609,000 | -11.8% | 417,990 | -1.1% | 3.86% | -4.0% |
| Q4 2021 | $139,061,000 | +7.5% | 422,665 | -0.5% | 4.02% | -1.7% |
| Q3 2021 | $129,314,000 | +12.4% | 424,761 | -1.0% | 4.09% | +13.8% |
| Q2 2021 | $115,095,000 | +17.0% | 428,883 | -1.9% | 3.60% | +10.1% |
| Q1 2021 | $98,388,000 | -1.4% | 437,126 | -2.6% | 3.27% | -7.9% |
| Q4 2020 | $99,737,000 | -3.0% | 448,984 | -5.9% | 3.55% | -9.7% |
| Q3 2020 | $102,779,000 | +19.1% | 477,309 | -2.2% | 3.93% | +8.9% |
| Q2 2020 | $86,281,000 | +14.1% | 487,929 | -10.7% | 3.61% | +1.3% |
| Q1 2020 | $75,639,000 | -12.0% | 546,483 | -2.5% | 3.56% | +20.9% |
| Q4 2019 | $85,983,000 | +4.9% | 560,224 | -1.3% | 2.95% | -3.2% |
| Q3 2019 | $81,971,000 | +2.0% | 567,545 | +0.9% | 3.04% | -0.6% |
| Q2 2019 | $80,357,000 | +0.1% | 562,248 | -7.6% | 3.06% | +4.3% |
| Q1 2019 | $80,299,000 | +25.4% | 608,230 | -2.0% | 2.94% | -9.1% |
| Q4 2018 | $64,019,000 | -7.6% | 620,818 | -2.6% | 3.23% | +36.0% |
| Q3 2018 | $69,273,000 | +12.4% | 637,519 | +2.1% | 2.38% | +7.1% |
| Q2 2018 | $61,625,000 | -1.9% | 624,494 | -2.7% | 2.22% | -3.5% |
| Q1 2018 | $62,850,000 | -4.1% | 641,914 | -0.8% | 2.30% | +1.7% |
| Q4 2017 | $65,508,000 | +18.9% | 646,799 | +0.7% | 2.26% | +6.2% |
| Q3 2017 | $55,084,000 | -3.2% | 642,150 | -4.8% | 2.13% | -6.5% |
| Q2 2017 | $56,930,000 | -3.0% | 674,600 | -1.7% | 2.28% | +1.4% |
| Q1 2017 | $58,710,000 | +7.4% | 686,420 | -2.3% | 2.24% | +1.0% |
| Q4 2016 | $54,688,000 | -0.6% | 702,570 | +0.1% | 2.22% | -5.8% |
| Q3 2016 | $55,030,000 | -23.2% | 702,003 | -1.0% | 2.36% | -26.4% |
| Q2 2016 | $71,638,000 | +5.9% | 709,286 | -0.5% | 3.21% | +4.2% |
| Q1 2016 | $67,639,000 | +4.6% | 713,045 | +2.4% | 3.08% | +2.2% |
| Q4 2015 | $64,652,000 | +11.3% | 696,085 | +2.1% | 3.01% | +3.9% |
| Q3 2015 | $58,093,000 | +0.2% | 681,767 | +0.6% | 2.90% | +9.0% |
| Q2 2015 | $57,995,000 | +0.2% | 677,592 | -0.7% | 2.66% | +1.3% |
| Q1 2015 | $57,906,000 | -0.2% | 682,052 | +0.7% | 2.63% | -5.9% |
| Q4 2014 | $58,030,000 | +24.1% | 677,055 | +10.0% | 2.79% | +8.7% |
| Q3 2014 | $46,776,000 | -7.6% | 615,636 | -4.3% | 2.57% | -4.5% |
| Q2 2014 | $50,623,000 | +3.5% | 643,001 | -1.4% | 2.69% | +0.3% |
| Q1 2014 | $48,931,000 | -5.8% | 652,411 | -3.0% | 2.68% | -8.3% |
| Q4 2013 | $51,946,000 | +8.8% | 672,873 | -2.3% | 2.92% | +0.6% |
| Q3 2013 | $47,730,000 | +7.7% | 688,548 | -1.7% | 2.90% | +2.4% |
| Q2 2013 | $44,336,000 | – | 700,413 | – | 2.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |